AltMountain

Silverarc Capital Management, LLC

Boston, MA · CRD 304220
Hedge fund manager

Silverarc Capital Management, LLC is an SEC-registered investment adviser based in Boston, MA that reports managing 2 hedge funds on Form ADV. It reports $1.6 billion in regulatory assets under management. Its private funds, of all types, hold $935.3 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +28.2% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +113.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$1.6 billionForm ADV Item 5.F
Gross assets of private funds
$935.3 millionAll private fund types, Form ADV
Hedge funds managed
23 private funds in total
Employees
9Form ADV Item 5.A
Registration
SEC-registered adviserCRD 304220
Latest Form ADV
03/30/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+28.2%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+113.6%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$898.5 million65 positions, 2026-06-30
$88$151$214Q3 2024Q1 2025Q3 2025Q1 202613F est. $214S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+20.4%+14.8%
Q1 2026+6.5%-4.6%
Q4 2025+26.1%+2.4%
Q3 2025+32.4%+7.8%
Q2 2025+13.7%+10.4%
Q1 2025-12.1%-4.5%
Q4 2024-4.5%+2.1%
Q3 2024+4.6%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 63 share positions ($820,947,677) reported by Silverarc Capital Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 12, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Kodiak Sciences Inc8.66%
  • Celcuity Inc7.78%
  • Cogent Biosciences Inc6.14%
  • Urogen Pharma LTD5.68%
  • Immunome Inc5.48%
  • Monte Rosa Therapeutics Inc4.52%
  • Sagimet Biosciences Inc4.51%
  • Ascendis Pharma A/s4.22%
  • Rhythm Pharmaceuticals Inc4.04%
  • Biogen Inc3.10%
StockValue% of 13F portfolioSharesShares vs prior quarter
Kodiak Sciences Inc$71,116,1168.66%750,170+37.33%
Celcuity Inc$63,869,9077.78%803,193+60.32%
Cogent Biosciences Inc$50,421,8306.14%1,574,698+22.96%
Urogen Pharma LTD$46,671,2345.68%1,148,689-11.77%
Immunome Inc$45,014,3005.48%2,092,715+3.75%
Monte Rosa Therapeutics Inc$37,135,3824.52%3,112,773-6.38%
Sagimet Biosciences Inc$37,010,3814.51%3,745,990+27.95%
Ascendis Pharma A/s$34,670,0304.22%152,175-26.21%
Rhythm Pharmaceuticals Inc$33,165,0034.04%348,317+11.83%
Biogen Inc$25,477,0053.10%112,790+134.49%
Immunovant Inc$21,080,5782.57%624,055+0.80%
Dianthus Therapeutics Inc$20,831,0452.54%236,582-39.34%
Oruka Therapeutics Inc$20,649,0902.52%247,918-29.73%
Erasca Inc$19,504,4702.38%1,330,455+5.34%
Abivax SA$17,397,7152.12%175,699+3.60%
Celldex Therapeutics Inc New$15,802,7591.92%487,589New
Ovid Therapeutics Inc$14,815,5001.80%5,950,000+91.87%
Spyre Therapeutics Inc$13,456,9741.64%151,151+152.09%
Definium Therapeutics Inc$13,166,7051.60%345,946-13.51%
Helix Acquisition Corp III$12,829,2791.56%1,208,030+2.56%
Alkermes PLC$12,173,3021.48%300,427+164.71%
C4 Therapeutics Inc$11,503,9751.40%3,454,647+13.94%
Avalyn Pharmaceuticals Inc$10,779,2481.31%378,352+14.48%
Cerus Corp$9,402,4161.15%3,950,595+13.76%
Alx Oncology Hldgs Inc$9,126,6841.11%6,565,960+14.29%
Zenas Biopharma Inc$9,009,5171.10%334,057-34.47%
Compass Pathways PLC$8,923,9091.09%717,356+42.51%
Rainier Acquisition Corp$8,709,5251.06%853,875New
Compugen LTD$8,536,5481.04%3,586,785+12.64%
Savara Inc$7,837,1780.95%1,518,833+12.05%
Vaxcyte Inc$7,117,0520.87%125,080-13.74%
Yarrow Bioscience Inc$6,799,2160.83%301,919New
Ibio Inc$6,321,3640.77%5,357,088+52.17%
Arcturus Therapeutics Hldgs$6,296,0170.77%459,899New
Praxis Precision Medicines I$5,752,6660.70%19,753-69.92%
Kiniksa Pharmaceuticals Intl$5,647,7530.69%75,697New
Enliven Therapeutics Inc$5,567,3600.68%121,452-75.18%
Solid Biosciences Inc$5,497,2370.67%760,337+13.75%
Evommune Inc$4,906,6630.60%594,027New
Syndax Pharmaceuticals Inc$4,651,4580.57%247,418-79.63%
Benitec Biopharma Inc$4,431,0900.54%443,109-34.82%
Research Alliance Corp III$4,383,2040.53%404,728+12.42%
Blossomhill Therapeutics Inc$3,767,2190.46%202,104New
Faeth Therapeutics Inc$3,690,6750.45%124,098New
Abeona Therapeutics Inc$3,640,5650.44%693,441+13.60%
Research Alliance Corp IV$3,501,9160.43%301,962New
Adlai Nortye LTD$3,465,8720.42%216,617New
Palisade Bio Inc$3,153,0630.38%2,335,602New
Disc Medicine Inc$3,097,0440.38%47,312-42.86%
Tela Bio Inc$2,457,7810.30%2,137,201Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 15 new positions, 17 sold out, 25 increased, 21 reduced and 2 unchanged.

Number of positions (a count, not dollars)

  • New positions15
  • Increased25
  • Unchanged2
  • Reduced21
  • Sold out17

New positions

StockValueShares
Celldex Therapeutics Inc New$15,802,759487,589
Rainier Acquisition Corp$8,709,525853,875
Yarrow Bioscience Inc$6,799,216301,919
Arcturus Therapeutics Hldgs$6,296,017459,899
Kiniksa Pharmaceuticals Intl$5,647,75375,697
Evommune Inc$4,906,663594,027
Blossomhill Therapeutics Inc$3,767,219202,104
Faeth Therapeutics Inc$3,690,675124,098
Research Alliance Corp IV$3,501,916301,962
Adlai Nortye LTD$3,465,872216,617
Palisade Bio Inc$3,153,0632,335,602
Zevra Therapeutics Inc$2,196,852200,260
Moderna Inc$1,925,70010,000
Rapport Therapeutics Inc$1,193,60635,524
Zura Bio LTD$416,000100,000

Sold out

StockValue at Jun 30, 2026Shares held then
Veracyte Inc$18,676,199318,001
Guardant Health Inc$14,976,89599,826
Trevi Therapeutics Inc$12,646,472678,095
Veradermics Inc$11,679,30095,000
Xenon Pharmaceuticals Inc$11,276,516186,821
Avalo Therapeutics Inc$9,247,429500,402
Genedx Holdings Corp$8,393,767122,269
Artiva Biotherapeutics Inc$5,092,500525,000
Insmed Inc$3,671,78034,438
Karyopharm Therapeutics Inc$2,906,184297,460
Revolution Medicines Inc$1,872,80010,000
Sionna Therapeutics Inc$1,868,60742,478
Fractyl Health Inc$1,301,2081,637,976
Connect Biopharma Hldgs LTD$1,297,100545,000
Crescent Biopharma Inc.$1,063,87259,104
Foghorn Therapeutics Inc$224,35845,975
Rocket Pharmaceuticals Inc$356104,828

Largest increases

StockChange in sharesChangeValue nowShares now
Celcuity Inc+302,197+60.32%$63,869,907803,193
Kodiak Sciences Inc+203,914+37.33%$71,116,116750,170
Biogen Inc+64,689+134.49%$25,477,005112,790
Cogent Biosciences Inc+293,991+22.96%$50,421,8301,574,698
Spyre Therapeutics Inc+91,192+152.09%$13,456,974151,151
Sagimet Biosciences Inc+818,292+27.95%$37,010,3813,745,990
Alkermes PLC+186,933+164.71%$12,173,302300,427
Ovid Therapeutics Inc+2,848,871+91.87%$14,815,5005,950,000
Rhythm Pharmaceuticals Inc+36,856+11.83%$33,165,003348,317
Compass Pathways PLC+213,974+42.51%$8,923,909717,356
Ibio Inc+1,836,598+52.17%$6,321,3645,357,088
Immunome Inc+75,706+3.75%$45,014,3002,092,715
C4 Therapeutics Inc+422,587+13.94%$11,503,9753,454,647
Avalyn Pharmaceuticals Inc+47,865+14.48%$10,779,248378,352
Alx Oncology Hldgs Inc+821,203+14.29%$9,126,6846,565,960
Cerus Corp+477,858+13.76%$9,402,4163,950,595
Erasca Inc+67,429+5.34%$19,504,4701,330,455
Compugen LTD+402,528+12.64%$8,536,5483,586,785
Savara Inc+163,374+12.05%$7,837,1781,518,833
Solid Biosciences Inc+91,887+13.75%$5,497,237760,337

Largest reductions

StockChange in sharesChangeValue nowShares now
Syndax Pharmaceuticals Inc-966,972-79.63%$4,651,458247,418
Enliven Therapeutics Inc-367,930-75.18%$5,567,360121,452
Dianthus Therapeutics Inc-153,418-39.34%$20,831,045236,582
Praxis Precision Medicines I-45,926-69.92%$5,752,66619,753
Ascendis Pharma A/s-54,059-26.21%$34,670,030152,175
Aclaris Therapeutics Inc-1,707,941-87.74%$1,254,726238,541
Oruka Therapeutics Inc-104,884-29.73%$20,649,090247,918
Oric Pharmaceuticals Inc-578,321-78.27%$2,162,635160,552
Urogen Pharma LTD-153,290-11.77%$46,671,2341,148,689
Zenas Biopharma Inc-175,732-34.47%$9,009,517334,057
Monte Rosa Therapeutics Inc-212,112-6.38%$37,135,3823,112,773
Benitec Biopharma Inc-236,717-34.82%$4,431,090443,109
Disc Medicine Inc-35,488-42.86%$3,097,04447,312
Definium Therapeutics Inc-54,054-13.51%$13,166,705345,946
Camp4 Therapeutics Corp-470,531-71.99%$739,575183,063
Contineum Therapeutics Inc-137,171-46.32%$2,133,297158,964
Uniqure NV-48,296-46.00%$1,369,96956,704
Vaxcyte Inc-19,920-13.74%$7,117,052125,080
Achieve Life Science Inc-68,228-30.03%$1,285,906158,950
Cellectar Biosciences Inc-170,610-53.03%$278,057151,118

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Rainier Acquisition Corp.13G9.67%853,875Nov 13, 2026SEC.gov ↗
IRulya Therapeutics Inc13G7.9%880,255Nov 13, 2026SEC.gov ↗
Sagimet Biosciences Inc13G6.1%3,745,990Nov 13, 2026SEC.gov ↗
Tela Bio, Inc.13G amendment4.8%2,137,201Aug 14, 2026SEC.gov ↗
Kalvista Pharmaceuticals, Inc.13G amendment0%0Aug 14, 2026SEC.gov ↗
Elutia Inc.13G amendment4.9%2,192,980Aug 14, 2026SEC.gov ↗
Cellectar Biosciences Inc13G9.99%851,285Aug 14, 2026SEC.gov ↗
NextCure, INC.13G amendment4.9%176,057May 13, 2026SEC.gov ↗
Helix Acquisition Corp. III13G6.8%1,208,986May 13, 2026SEC.gov ↗
Fractyl Health Inc13G amendment2.3%3,606,386May 13, 2026SEC.gov ↗
Avalo Therapeutics, Inc.13G2.83%524,436Feb 10, 2026SEC.gov ↗
iBio, Inc.13G9.99%2,181,422Nov 14, 2025SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (3)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Venture capital funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Silverarc Capital Alpha Fund II, L.P.
Delaware, United StatesHedge fund
Gross assets$460M
Minimum$1.0M
Owners81
AdviserSilverarc Capital Management, LLC
Silverarc Capital Alpha Fund I, L.P.
Delaware, United StatesHedge fund
Gross assets$24.8M
Minimum$250K
Owners24
AdviserSilverarc Capital Management, LLC

As reported in the adviser's Form ADV filed Jun 4, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠